PMID- 38381231
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240224
IS  - 2194-7791 (Print)
IS  - 2194-7791 (Electronic)
IS  - 2194-7791 (Linking)
VI  - 11
IP  - 1
DP  - 2024 Feb 21
TI  - Adverse effects of remdesivir for the treatment of acute COVID-19 in the 
      pediatric population: a retrospective observational study.
PG  - 2
LID - 10.1186/s40348-024-00175-9 [doi]
LID - 2
AB  - BACKGROUND: Although the severity of coronavirus disease 2019 (COVID-19) tends to 
      be lower in children, it can still lead to severe illness, particularly among 
      those with chronic medical conditions. While remdesivir (RDV) is one of the few 
      approved antiviral treatments for COVID-19 in children in many countries, the 
      available data on the safety of RDV in this population is limited. METHODS: To 
      address this knowledge gap, a multicenter study involving 65 patients 
      retrospectively analyzed the clinical data from individuals aged <18 who were 
      hospitalized due to severe COVID-19 (defined as SpO(2) < 94% or requiring 
      supplemental oxygen) and received at least one dose of RDV. Additionally, the 
      study encompassed 22 patients with mild-moderate COVID-19 who were considered at 
      high risk of developing severe disease. RESULTS: Nineteen children (29%) 
      experienced mild-to-moderate adverse events (AEs) attributed to RDV, including 
      transaminitis in 20% of children, bradycardia in 8%, and hypotension in 5%. AEs 
      did not require discontinuation of RDV, except in one patient who developed 
      premature ventricular contractions. The rate of AEs did not differ between 
      patients with severe COVID-19 and those with mild-moderate COVID-19 but at high 
      risk for severe disease. All but one patient were discharged within 23 days of 
      admission, and no fatalities were recorded. Among high-risk patients with 
      mild-moderate disease, only 2 (9%) progressed to the point of needing 
      supplemental oxygen. CONCLUSIONS: Our data suggests that RDV is safe in children, 
      with no reported serious AEs. However, the absence of a control group limits the 
      extent to which conclusions can be drawn. RDV may contribute to clinical 
      improvement, particularly in high-risk patients.
CI  - (c) 2024. The Author(s).
FAU - Schulz, Abigail
AU  - Schulz A
AD  - University of Illinois College of Medicine at Peoria, 530 NE Glen Oak Avenue, 
      North Building #6606, Peoria, IL, 61637, USA.
FAU - Huynh, Natalie
AU  - Huynh N
AD  - Department of Pediatrics, University of Illinois College of Medicine at Peoria, 
      530 NE Glen Oak Avenue, North Building #6606, Peoria, IL, 61637, USA.
FAU - Heger, Margaret
AU  - Heger M
AD  - Department of Pharmacy, OSF HealthCare Children's Hospital of Illinois, Peoria, 
      IL, USA.
FAU - Bakir, Mustafa
AU  - Bakir M
AD  - Department of Pediatrics, Division of Pediatric Infectious Diseases, University 
      of Illinois College of Medicine at Peoria, 530 NE Glen Oak Avenue, North Building 
      #6606, Peoria, IL, 61637, USA. mbakir@uic.edu.
LA  - eng
PT  - Journal Article
DEP - 20240221
PL  - Germany
TA  - Mol Cell Pediatr
JT  - Molecular and cellular pediatrics
JID - 101660689
PMC - PMC10881938
OTO - NOTNLM
OT  - Adverse effects
OT  - Children
OT  - Remdesivir
COIS- The authors declare no competing interests.
EDAT- 2024/02/21 12:43
MHDA- 2024/02/21 12:44
PMCR- 2024/02/21
CRDT- 2024/02/21 11:09
PHST- 2023/11/22 00:00 [received]
PHST- 2024/02/05 00:00 [accepted]
PHST- 2024/02/21 12:44 [medline]
PHST- 2024/02/21 12:43 [pubmed]
PHST- 2024/02/21 11:09 [entrez]
PHST- 2024/02/21 00:00 [pmc-release]
AID - 10.1186/s40348-024-00175-9 [pii]
AID - 175 [pii]
AID - 10.1186/s40348-024-00175-9 [doi]
PST - epublish
SO  - Mol Cell Pediatr. 2024 Feb 21;11(1):2. doi: 10.1186/s40348-024-00175-9.